公司状况目前公开资料中暂无其他明确即将发生的重大事件时间表。公司主营业务为电网设备，长期可 关注行业政策及业绩披露等常规节点。 以上内容基于公开资料整理，不构成投资建议。 经济观察网 宏力达（688330）公告拟以3.41亿元收购中腾微网（北京）科技有限公司50.93%股权，交 易完成后持股比例将升至60.01%，中腾微网将被纳入合并报表范围。该交易尚需履行内部决策及监管 审批程序。 ...

Group 1 - The company has released a performance forecast, expecting a net profit attributable to shareholders of approximately 635 million yuan for 2025, representing a year-on-year increase of 185.09%, although final figures will depend on the officially audited annual report [2] - The company plans to use approximately 341 million yuan of raised funds to acquire a 50.9323% stake in Zhongteng Weiwang (Beijing) Technology Co., Ltd., which will increase its total stake to 60.0053% and include it in the consolidated financial statements [3] - The company intends to jointly increase capital in Yanchao Juneng (Shanghai) Technology Co., Ltd. with its related party, Shanghai Hongyuan Investment Group Co., Ltd., with both parties contributing 15 million yuan each, resulting in the company holding approximately 3.26% of the shares post-transaction [4] Group 2 - On February 10, 2026, the company's stock price closed at 46.82 yuan, down 2.35% for the day, with a trading volume of 210 million yuan [5]

Core Viewpoint - Dier Medical faces significant challenges, including its first annual loss since its listing, due to internal control issues and a declining market environment in the IVD industry [1][2][7] Group 1: Financial Performance - In 2025, Dier Medical's revenue is projected to decline by 60.12% year-on-year to 469 million yuan, with a net profit of -87 million yuan, marking a 145.31% year-on-year decrease [2][4] - The company anticipates a total loss of at least 1 billion yuan in Q4 2025, with no signs of stabilization [4] - The operating cash flow has seen a net outflow of 580 million yuan in the first three quarters of 2025, following a 299 million yuan outflow in 2024 [4] Group 2: Market Environment - The IVD industry is experiencing a downturn, with A-share IVD sector revenues dropping by 14.5% year-on-year to 27.62 billion yuan in the first three quarters of 2025, and net profits down by 26.4% to 4.49 billion yuan [2] - Dier Medical's performance is lagging behind the industry, with its revenue and profit both declining significantly [2] Group 3: Operational Challenges - The company's gross margin for instrument business plummeted from 33.99% in 2023 to 9.68% in the first half of 2025, while reagent gross margin fell from 75.42% to 60.53% [4] - Dier Medical's business structure is heavily weighted towards instruments rather than reagents, which is contrary to the industry norm of "instruments attract customers, reagents generate profit" [4][5] Group 4: Internal Control Issues - The company received a corrective order from the Jilin Securities Regulatory Bureau for improper revenue recognition and inadequate internal controls, leading to an overstatement of revenue by 3.693 million yuan and profit by 716,000 yuan in 2023 [1][7] - The company has reported a significant increase in credit impairment losses and asset impairment losses, totaling over 25.8 million yuan in the first three quarters of 2025 [5] Group 5: Governance and Strategic Challenges - Despite the acquisition by China Resources Group for 1.8 billion yuan, the expected synergies have not materialized, and the company's performance continues to decline [8] - Dier Medical has launched 14 new products in 2025, but faces stiff competition from domestic leaders and foreign brands in high-end markets [9]

（编辑 任世碧） 证券日报网讯 2月6日，宏力达在互动平台回答投资者提问时表示，公司始终坚持规范运作，严格按照 企业会计准则等相关要求编制财务报表，年度财务报表需经会计师事务所审计，确保数据真实、准确、 完整。 ...

证券日报网讯2月6日，宏力达在互动平台回答投资者提问时表示，公司将持续关注政策动向，把握市场 机遇，通过技术创新与产品优化，不断提升产品质量和服务水平，持续进行市场拓展。 ...

Group 1 - The company, Honglida, has a range of main products including smart pole-mounted switches, fault indicators, and grounding fault judgment auxiliary devices [2] - After years of product research and technological innovation, the company has accumulated a strong technical foundation and research capabilities [2] - The developed smart switches and other products can effectively enhance the convenience and reliability of power distribution line operation and maintenance [2]

证券日报网讯2月6日，宏力达在互动平台回答投资者提问时表示，公司作为有限合伙人认缴嘉兴久奕鑫 芫新能源创业投资合伙企业(有限合伙)基金份额，截至目前久奕鑫芫持有上海壁仞科技股份有限公司 0.6050%股份，穿透计算后公司间接持有壁仞科技约0.2192%股份。公司对壁仞科技的间接持股比例较 小，请广大投资者注意投资风险。 ...

证券日报网讯 2月6日，宏力达在互动平台回答投资者提问时表示，公司严格遵守中国证监会和上海证 券交易所对募集资金使用的规定，规范使用募集资金。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article is that Honglida has clarified that the recent share reduction by certain shareholders is a personal action and the company has complied with relevant laws and regulations regarding information disclosure [2] Group 2 - Honglida responded to investor inquiries on its interactive platform regarding shareholder actions [2] - The company emphasized its adherence to legal and regulatory requirements in disclosing information related to shareholder activities [2]

国浩律师（上海）事务所 股东会法律意见书 国浩律师（上海）事务所 关于上海宏力达信息技术股份有限公司 2026 年第一次临时股东会的法律意见书 致：上海宏力达信息技术股份有限公司 上海宏力达信息技术股份有限公司（以下简称"公司"）2026 年第一次临时 股东会（以下简称"本次股东会"）于 2026 年 2 月 2 日召开，国浩律师（上海） 事务所（以下简称"本所"）接受公司的委托，指派律师（以下简称"本所律师"） 出席会议，并依据《中华人民共和国证券法》《中华人民共和国公司法》《上市公 司股东会规则》和《上海宏力达信息技术股份有限公司章程》（以下简称"《公司 章程》"）出具本法律意见书。 本所律师已经按照有关法律、法规及规范性文件的规定对公司本次股东会召 集、召开程序是否合法以及是否符合《公司章程》、出席或列席会议人员的资格、 召集人资格的合法有效性和股东会表决程序、表决结果的合法有效性发表法律意见。 法律意见书中不存在虚假、严重误导性陈述及重大遗漏，否则愿意承担相应的法律 责任。 本所律师是根据对事实的了解和对法律的理解发表法律意见。 本法律意见书依据国家有关法律、法规及规范性文件的规定而出具。 本所律师同 ...